Raras
Buscar doenças, sintomas, genes...
Hiperparatireoidismo genético
ORPHA:208596DOENÇA RARA

Um caso de hiperparatireoidismo causado por uma modificação genômica herdada em um indivíduo.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um caso de hiperparatireoidismo causado por uma modificação genômica herdada em um indivíduo.

🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
27 sintomas
🦴
Ossos e articulações
23 sintomas
🫃
Digestivo
21 sintomas
🫘
Rins
12 sintomas
😀
Face
7 sintomas
🧠
Neurológico
4 sintomas

+ 72 sintomas em outras categorias

Características mais comuns

Ponte nasal ampla
Osteoporose generalizada
Dor mandibular
Sintoma abdominal
Condrocalcinose
Fibroma
176sintomas
Sem dados (176)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 176 características clínicas mais associadas, ordenadas por frequência.

Ponte nasal amplaWide nasal bridge
Osteoporose generalizadaGeneralized osteoporosis
Dor mandibularMandibular pain
Sintoma abdominalAbdominal symptom
CondrocalcinoseChondrocalcinosis

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa2
Últimos 10 anos200publicações
Pico2025164 papers
Linha do tempo
2024Hoje · 2026🧪 1993Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

7 genes identificados com associação a esta condição.

CDC73ParafibrominDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (7)
Formation of the beta-catenin:TCF transactivating complexHedgehog 'on' stateFormation of RNA Pol II elongation complex RNA Polymerase II Transcription ElongationRNA Polymerase II Pre-transcription Events
MECANISMO DE DOENÇA

Hyperparathyroidism 1

An autosomal dominant disorder characterized by hypercalcemia, elevated parathyroid hormone (PTH) levels, and uniglandular or multiglandular parathyroid hyperplasia, adenomas, and carcinomas.

OUTRAS DOENÇAS (4)
hyperparathyroidism 1hyperparathyroidism 2 with jaw tumorsparathyroid gland carcinomafamilial isolated hyperparathyroidism
HGNC:16783UniProt:Q6P1J9
CDKN2BCyclin-dependent kinase 4 inhibitor BCandidate gene tested inTolerante
FUNÇÃO

Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (5)
Cyclin D associated events in G1Senescence-Associated Secretory Phenotype (SASP)Oncogene Induced SenescenceOxidative Stress Induced SenescenceSMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
OUTRAS DOENÇAS (2)
familial melanomamultiple endocrine neoplasia type 1
HGNC:1788UniProt:P42772
CDKN1BCyclin-dependent kinase inhibitor 1BCandidate gene tested inModerado
FUNÇÃO

Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA (PubMed:28666995). Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its ph

LOCALIZAÇÃO

NucleusCytoplasmEndosome

VIAS BIOLÓGICAS (10)
Cyclin D associated events in G1Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)SCF(Skp2)-mediated degradation of p27/p21TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle ArrestDNA Damage/Telomere Stress Induced Senescence
MECANISMO DE DOENÇA

Multiple endocrine neoplasia 4

Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.

OUTRAS DOENÇAS (2)
multiple endocrine neoplasia type 4multiple endocrine neoplasia type 1
HGNC:1785UniProt:P46527
CASRExtracellular calcium-sensing receptorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

G-protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis (PubMed:17555508, PubMed:19789209, PubMed:21566075, PubMed:22114145, PubMed:22789683, PubMed:23966241, PubMed:25104082, PubMed:25292184, PubMed:25766501, PubMed:26386835, PubMed:32817431, PubMed:33603117, PubMed:34194040, PubMed:34467854, PubMed:7759551, PubMed:8636323, PubMed:8702647, PubMed:8878438). Senses fluctuations in the circulating cal

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsClass C/3 (Metabotropic glutamate/pheromone receptors)G alpha (q) signalling events
MECANISMO DE DOENÇA

Hypocalciuric hypercalcemia, familial 1

A form of hypocalciuric hypercalcemia, a disorder of mineral homeostasis that is transmitted as an autosomal dominant trait with a high degree of penetrance. It is characterized biochemically by lifelong elevation of serum calcium concentrations and is associated with inappropriately low urinary calcium excretion and a normal or mildly elevated circulating parathyroid hormone level. Hypermagnesemia is typically present. Affected individuals are usually asymptomatic and the disorder is considered benign. However, chondrocalcinosis and pancreatitis occur in some adults.

OUTRAS DOENÇAS (6)
autosomal dominant hypocalcemia 1familial hypocalciuric hypercalcemia 1neonatal severe primary hyperparathyroidismautosomal dominant hypocalcemia
HGNC:1514UniProt:P41180
GCM2Chorion-specific transcription factor GCMbDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription factor that binds specific sequences on gene promoters and activate their transcription. Through the regulation of gene transcription, may play a role in parathyroid gland development

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Hypoparathyroidism, familial isolated, 2

An autosomal recessive form of hypoparathyroidism, a disorder characterized by hypocalcemia and hyperphosphatemia due to a deficiency of parathyroid hormone. Clinical features include seizures, tetany and cramps.

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.4 TPM
Cerebelo
0.1 TPM
Cérebro - Hemisfério cerebelar
0.1 TPM
Cervix Ectocervix
0.0 TPM
Ovário
0.0 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (4)
hypoparathyroidism, familial isolated, 2hyperparathyroidism 4familial isolated hypoparathyroidism due to agenesis of parathyroid glandfamilial isolated hyperparathyroidism
HGNC:4198UniProt:O75603
MEN1MeninDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionDeactivation of the beta-catenin transactivating complexFormation of the beta-catenin:TCF transactivating complexFormation of WDR5-containing histone-modifying complexes
MECANISMO DE DOENÇA

Familial multiple endocrine neoplasia type I

Autosomal dominant disorder characterized by tumors of the parathyroid glands, gastro-intestinal endocrine tissue, the anterior pituitary and other tissues. Cutaneous lesions and nervous-tissue tumors can exist. Prognosis in MEN1 patients is related to hormonal hypersecretion by tumors, such as hypergastrinemia causing severe peptic ulcer disease (Zollinger-Ellison syndrome, ZES), primary hyperparathyroidism, and acute forms of hyperinsulinemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
45.1 TPM
Tireoide
43.2 TPM
Cérebro - Hemisfério cerebelar
40.2 TPM
Fibroblastos
37.9 TPM
Baço
35.0 TPM
OUTRAS DOENÇAS (7)
multiple endocrine neoplasia type 1pituitary gigantismnull pituitary adenomaprolactin-producing pituitary gland adenoma
HGNC:7010UniProt:O00255
TRPV6Transient receptor potential cation channel subfamily V member 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium selective cation channel that mediates Ca(2+) uptake in various tissues, including the intestine (PubMed:11097838, PubMed:11248124, PubMed:11278579, PubMed:15184369, PubMed:23612980, PubMed:29258289). Important for normal Ca(2+) ion homeostasis in the body, including bone and skin (By similarity). The channel is activated by low internal calcium level, probably including intracellular calcium store depletion, and the current exhibits an inward rectification (PubMed:15184369). Inactivatio

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
TRP channels
MECANISMO DE DOENÇA

Hyperparathyroidism, transient neonatal

An autosomal recessive disease characterized by impaired transplacental maternal-fetal transport of calcium, high serum PTH levels and signs of metabolic bone disease in the neonatal period. Skeletal anomalies include generalized osteopenia, narrow chest, short ribs with multiple healing fractures, and bowing or fractures of long bones. Affected individuals experience postnatal respiratory and feeding difficulties. The condition improves within a short time after birth once calcium is provided orally.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Próstata
57.8 TPM
Pâncreas
49.6 TPM
Skin Not Sun Exposed Suprapubic
19.6 TPM
Skin Sun Exposed Lower leg
16.5 TPM
Glândula salivar
15.0 TPM
OUTRAS DOENÇAS (3)
hyperparathyroidism, transient neonatalhereditary chronic pancreatitisneonatal severe primary hyperparathyroidism
HGNC:14006UniProt:Q9H1D0

Variantes genéticas (ClinVar)

1,943 variantes patogênicas registradas no ClinVar.

🧬 CDC73: NM_024529.5(CDC73):c.482A>G (p.Lys161Arg) ()
🧬 CDC73: NM_024529.5(CDC73):c.972+10T>C ()
🧬 CDC73: NM_024529.5(CDC73):c.1154+10T>C ()
🧬 CDC73: NM_024529.5(CDC73):c.370+14C>T ()
🧬 CDC73: NM_024529.5(CDC73):c.423+19A>G ()
Ver todas no ClinVar

Vias biológicas (Reactome)

35 vias biológicas associadas aos genes desta condição.

Formation of RNA Pol II elongation complex Formation of the beta-catenin:TCF transactivating complex Hedgehog 'on' state RNA Polymerase II Pre-transcription Events RNA Polymerase II Transcription Elongation E3 ubiquitin ligases ubiquitinate target proteins Dengue virus activates/modulates innate and adaptive immune responses SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol DNA Damage/Telomere Stress Induced Senescence RHO GTPases activate CIT Constitutive Signaling by AKT1 E17K in Cancer TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates Cell Cycle FLT3 Signaling FOXO-mediated transcription of cell cycle genes Estrogen-dependent nuclear events downstream of ESR-membrane signaling Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) G alpha (q) signalling events G alpha (i) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors) Deactivation of the beta-catenin transactivating complex Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) RHO GTPases activate IQGAPs Post-translational protein phosphorylation Formation of WDR5-containing histone-modifying complexes TRP channels

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Hiperparatireoidismo genético

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Treating microsatellite unstable metastatic parathyroid carcinoma with anti-PD1 therapy.

JCEM case reports2026 Apr

Parathyroid carcinoma (PC) is a rare endocrine malignancy that often clinically mimics primary hyperparathyroidism (PHPT) caused by parathyroid adenoma or hyperplasia. Complete resection of malignancy is the only curative treatment, and to date, there is no effective systemic therapy for advanced disease. A 60-year-old woman was referred for evaluation of hypercalcemia. Laboratory studies were consistent with PHPT. She underwent right superior parathyroidectomy, and pathology revealed PC with lymphovascular invasion. Postoperatively, calcium and parathyroid hormone levels normalized but recurred 6 months later. Imaging identified metastatic PC. Somatic genetic testing revealed a MutS homolog 2 (MSH2) splice-site mutation, indicating microsatellite instability. The patient started pembrolizumab immunotherapy, resulting in normalization of laboratory values and partial regression of metastases. This case highlights the diagnostic challenges of PC and underscores the potential role of immunotherapy in selected patients, particularly those with microsatellite instability, given the absence of established systemic treatment options.

#2

How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.

Annales d'endocrinologie2026 Mar 20

The discovery of RET as the primary driver of hereditary medullary thyroid cancer in multiple endocrine neoplasia syndrome drastically changed the diagnosis, management, and prognosis of patients with this rare endocrine tumor. First, from a diagnostic viewpoint, RET testing within families became possible, ruling out unnecessary follow-up for negative patients and proposing an adapted surveillance protocol for positive patients. Second, large-scale epidemiological studies paved the way for early "prophylactic" thyroidectomy, rendering a historically fatal disease curable. RET identification also allowed for proper screening of pheochromocytoma and primary hyperparathyroidism. Lastly, RET identification enabled the synthesis of new, highly effective, and well-tolerated specific inhibitors, which changed the outcome for patients with metastatic disease. The RET discovery is thus a perfect example of how gene discovery can transform the fate of a rare syndrome, and this is what will be described in this short review.

#3

A novel homozygous inactivating mutation of the calcium-sensing receptor causing familial hypocalciuric hypercalcemia complicated with primary hyperparathyroidism due to parathyroid adenoma: A case report.

The Journal of international medical research2026 Mar

Familial hypocalciuric hypercalcemia is an autosomal dominant genetic disorder characterized by mild to moderate hypercalcemia, mild hypermagnesemia, and normal or inappropriately elevated parathyroid hormone levels. Familial hypocalciuric hypercalcemia 1 is the most prevalent form of familial hypocalciuric hypercalcemia and is typically caused by heterozygous loss-of-function mutations in the calcium-sensing receptor (CaSR) gene. Homozygous CaSR mutations are more commonly associated with neonatal severe primary hyperparathyroidism. We report the case of a female patient in her early 40s harboring a novel homozygous frameshift mutation in the CaSR gene (c.2603_2604insTT), resulting in familial hypocalciuric hypercalcemia 1. The patient presented with persistent hypocalciuria, hypercalcemia, and primary hyperparathyroidism, along with a family history of consanguinity. This case highlights the phenotypic variability associated with CaSR mutations and broadens the clinical spectrum of homozygous CaSR-related disorders. Increased clinical awareness of atypical genetic presentations is essential to avoid misdiagnosis and to ensure appropriate management of patients with familial disorders of calcium homeostasis.

#4

[Multiple endocrine neoplasia syndrome type 1: analysis of data from 102 patients from 43 families in the population of the Russian Federation].

Problemy endokrinologii2026 Mar 07

 Multiple endocrine neoplasia syndrome type 1 (MEN-1) is a rare, autosomal dominant disorder resulting from inactivating mutations in the MEN1 gene. It demonstrates high penetrance, with the "classic triad" of manifestations comprising primary hyperparathyroidism (PHPT), gastrointestinal neuroendocrine neoplasms (NEN), and pituitary adenomas. Diagnosis relies on clinical, familial, and genetic criteria. However, significant phenotypic variability and the lack of a clear genotype-phenotype correlation complicate early diagnosis.  To investigate the clinical-epidemiological, laboratory-instrumental, and genetic characteristics of familial MEN-1 in the Russian population.  We conducted a single-center, single-stage study (2015-2025) at the Endocrinology Research Centre enrolling 102 genetically confirmed MEN-1 patients from 43 families. Participants were stratified by age at PHPT onset (≤18 years, 19-40 years, and &gt;40 years) and MEN1 mutation type/location. We compared groups using calcium-phosphorus metabolism parameters, disease progression patterns, PHPT surgical outcomes, and genotype-phenotype correlations.  Cohort baseline characteristics (sex, manifestations) were comparable (p&gt;0,05), but we observed significant differences in NEN onset age (p&lt;0,001) and a trend toward higher pituitary adenoma prevalence (p=0,003). Exon 10 mutation were associated with a 7,7-fold increased pituitary adenoma risk (OR=7,7; p=0,006), though mutation type did not predict broader phenotype. Groups did not differ in multiglandular involvement, surgical outcomes, or histopathology (p&gt;0,05).  MEN-1 exhibits marked clinical heterogeneity in the Russian population, with exon 10 mutations significantly increasing pituitary adenoma risk. Early-onset PHPT predicts earlier NEN and pituitary adenoma development. These findings support proactive genetic screening and risk-stratified monitoring for MEN-1 families. ОБОСНОВАНИЕ. Синдром множественных эндокринных неоплазий 1 типа (МЭН-1) — редкое аутосомно-доминантное заболевание, обусловленное инактивирующими мутациями в гене MEN1. МЭН-1 характеризуется высокой пенетрантностью; к «классической триаде» проявлений синдрома относятся первичный гиперпаратиреоз (ПГПТ), нейроэндокринные неоплазии (НЭН) желудочно-кишечного тракта (ЖКТ) и аденомы гипофиза. Диагноз устанавливается на основании клинических, семейных и генетических критериев, однако фенотипическая вариабельность и отсутствие четкой генотип-фенотипической корреляции затрудняют раннюю диагностику заболевания. ЦЕЛЬ. Охарактеризовать клинико-эпидемиологические, лабораторно-инструментальные и генетические особенности семейных форм МЭН-1 в Российский Федерации. МАТЕРИАЛЫ И МЕТОДЫ. На базе ФГБУ «НМИЦ эндокринологии им. академика И.И. Дедова» Минздрава России проведено одноцентровое одномоментное исследование (102 пациента с генетически верифицированным МЭН-1 из 43 семей) за период 2015–2025 гг. Пациенты были разделены 3 группы в зависимости от возраста манифестации ПГПТ — в большинстве случаев «первого» компонента заболевания: ≤18 лет, 19–40 лет и >40 лет. Кроме того, все пациенты были сгруппированы в зависимости от типа и локализации мутации в гене MEN1. Проведен сравнительный анализ независимых групп и подгрупп по основным показателям кальций-фосфорного обмена, характеристикам проявлений, течению и исходам хирургического лечения ПГПТ, проанализирована генотип-фенотипическая корреляция МЭН-1. РЕЗУЛЬТАТЫ. Группы пациентов с МЭН-1 были сопоставимы по основным характеристикам (пол, первый компонент, другие проявления синдрома; p>0,05), однако выявлены значимые различия в возрасте манифестации НЭН (p<0,001) и тенденция для аденом гипофиза (p=0,003). При анализе генетических данных мы обнаружили ассоциацию между мутацией в 10-м экзоне гена MEN1 и риском развития аденом гипофиза (ОР=7,7; p=0,006), в то время как тип мутации никак не определял фенотип МЭН-1. Группы не различались по множественному характеру поражения околощитовидных желез (ОЩЖ), хирургическим исходам ПГПТ, а также гистологическим характеристикам образований ОЩЖ (p>0,05). ЗАКЛЮЧЕНИЕ. Анализ семейных форм МЭН-1 в российской популяции подтвердил высокую клиническую гетерогенность синдрома, включая ассоциацию мутаций в 10-м экзоне гена MEN1 с повышенным риском аденом гипофиза. У пациентов с манифестацией ПГПТ в более молодом возрасте отмечалось более раннее развитие НЭН ЖКТ и аденом гипофиза. Результаты исследования подтверждают необходимость раннего генетического скрининга и индивидуального мониторинга пациентов с МЭН-1, а также их родственников.

#5

Hyperparathyroidism drives periodontitis progression via parathyroid hormone-induced endoplasmic reticulum stress.

Biochemical and biophysical research communications2026 Apr 23

Given the high prevalence of periodontitis and potential for undetected primary hyperparathyroidism (pHPT) to exacerbate periodontal damage, managing pHPT in advanced periodontitis (stages III/IV) is critical. The causal link between pHPT and periodontitis remains unclear. This study aims to investigate the causal effect and mechanisms between hyperparathyroidism and periodontitis. A two-sample Mendelian randomization study used genome-wide association studies (GWAS) summary data to explore the causal link between hyperparathyroidism and periodontitis, employing single nucleotide polymorphisms (SNPs) as instrumental variables and methods like MR-Egger regression and Weighted median for robust results. PTH levels were detected on samples from both healthy and periodontitis-affected gingival tissues and gingival crevicular fluids. We assessed the impact of PTH on periodontal inflammation through treating gingival fibroblasts with PTH and detecting endoplasmic reticulum stress-related markers. Transcriptomics and metabolomics analyses were integrated to explore genetic pathways related to PTH. Hyperparathyroidism increased the risk of periodontitis, but analyses of periodontitis on hyperparathyroidism showed no reverse causality. PTH levels increased in gingival tissues and gingival crevicular fluid. Multi-omics analysis revealed significant gene and metabolite enrichment in calcium signaling and parathyroid hormone pathways. Since calcium ions are mainly from the endoplasmic reticulum, we focused on endoplasmic reticulum stress and found its effect on lessening PTH-induced periodontal inflammation. This study suggests that periodontitis may serve as a warning sign for pHPT, highlighting the importance of screening for hyperparathyroidism in periodontitis patients. The principal molecules involved in the endoplasmic reticulum stress pathway present promising therapeutic targets for improving periodontal health in patients with hyperparathyroidism.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 196

2026

Treating microsatellite unstable metastatic parathyroid carcinoma with anti-PD1 therapy.

JCEM case reports
2026

How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.

Annales d'endocrinologie
2026

A novel homozygous inactivating mutation of the calcium-sensing receptor causing familial hypocalciuric hypercalcemia complicated with primary hyperparathyroidism due to parathyroid adenoma: A case report.

The Journal of international medical research
2026

[Multiple endocrine neoplasia syndrome type 1: analysis of data from 102 patients from 43 families in the population of the Russian Federation].

Problemy endokrinologii
2025

Pediatric Hepatocyte Nuclear Factor 1B (HNF1B) Disease: Diabetes and Endocrine Manifestations.

Pediatric diabetes
2026

Hyperparathyroidism drives periodontitis progression via parathyroid hormone-induced endoplasmic reticulum stress.

Biochemical and biophysical research communications
2026

GRHL2/SENP1/VDR Signaling Axis: A Key Regulator of SUMOylation and Calcitriol Resistance in SHPT.

BioFactors (Oxford, England)
2026

Primary Hyperparathyroidism in the Pediatric Population: Surgical Considerations and Outcomes: A Narrative Review.

Diagnostics (Basel, Switzerland)
2026

Multiple endocrine neoplasia type 1 with MEN1 c.652C>T (p.Arg218Trp): variant reclassified to likely pathogenic.

JCEM case reports
2026

Severe pediatric hypocalcemia in Vietnam: etiologic profile, clinical outcomes and risk factors in 246 cases.

Frontiers in endocrinology
2026

Rare RET Variants in a Patient With MEN2A and Multiple Follicular-Derived Thyroid Tumors: A Case Report and Review of the Literature.

International journal of surgical pathology
2025

Case Report: Nephrocalcinosis from pancreatic hypoplasia in HNF1B disease: a multigenerational expression with genetic confirmation in the youngest generation.

Frontiers in medicine
2026

Multiple endocrine neoplasia type 5: emerging evidence and clinical perspectives.

Endocrine-related cancer
2026

Nephrocalcinosis: unveiling renal tubulopathies in the genomic era.

Jornal brasileiro de nefrologia
2026

Recurrent uterine adenofibroma revealed to be hyperparathyroidism-jaw tumor syndrome: Case report.

Radiology case reports
2026

H3-3A gene mutation analysis in giant cell tumor of bone and its histologic mimics: A single institutional study from India.

Annals of diagnostic pathology
2026

[18F]Fluorocholine PET/CT in a 15-year-old patient suggested HPT-JT syndrome with active cemento-ossifying fibroma.

EJNMMI research
2025

Basal Ganglia Calcifications for Nephrologists: Fahr/Primary Familial Brain Calcification (PFBC) at the Interface of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) and Hypoparathyroidism.

Cureus
2026

Transient neonatal hyperparathyroidism caused by a monoallelic TRPV6 dominant negative variant.

JBMR plus
2026

Cinacalcet therapy in symptomatic 11-year-old girl with familial hypocalciuric hypercalcemia type 3.

Pediatric nephrology (Berlin, Germany)
2025

Targeted Next-Generation Sequencing of MEN 1, RET, CDC 73, and CDKNIB Genes in Familial Primary Hyperparathyroidism: A Study from Northern India.

Indian journal of endocrinology and metabolism
2025

Multiple Endocrine Neoplasia Type 5 due to Germline MAX Mutations: A Systematic Review of Tumor Spectrum and Clinical Features.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Atypical presentation of HNF1β gene mutation mimicking type 2 diabetes: Case report and literature review.

SAGE open medical case reports
2026

CYP24A1: the pivotal regulator of vitamin D homeostasis, pathophysiology in metabolic and genetic disease, and emerging target for precision medicine.

Drug metabolism reviews
2025

Burosumab in adults with X-linked hypophosphatemia: real-world experience from a retrospective study in Sydney.

JBMR plus
2025

Management of Neonatal Severe Hyperparathyroidism due to Homozygous CASR Mutation: Challenges and Literature Insights.

Molecular syndromology
2025

The predictive value of 24-hour urinary calcium for kidney stone risk in primary hyperparathyroidism: insight from a retrospective study of parathyroid adenoma cases.

Frontiers in endocrinology
2025

Refractory hypercalcemic crisis: A case of primary hyperparathyroidism with Gitelman syndrome.

The Journal of international medical research
2026

A Challenging Case of Hypercalcemia Caused by a Novel Homozygous Variant Missense Mutation in the CYP24A1 Gene.

JCEM case reports
2025

[The 514th case: urinary stone excretion, elevated blood glucose, pancreatic mass,and co-secretion of multiple hormones].

Zhonghua nei ke za zhi
2025

Case Report: Novel likely pathogenic MEN1 mosaic mutation in the family with MEN-1 syndrome.

Frontiers in endocrinology
2026

Dysregulated neutrophils contribute to bone loss in renal osteodystrophy by enhancing osteoclastogenesis: Insights from integrated bioinformatics and experimental validation.

International immunopharmacology
2025

A Hypercalcemic Deception: Uncovering an Unusual Case of Familial Hypocalciuric Hypercalcemia.

Cureus
2025

Recurrent Nephrolithiasis and Beyond: The Long Diagnostic Odyssey of a Case of CLDN16 Mutation.

Clinical case reports
2025

EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology.

Hormone research in paediatrics
2025

Double Parathyroid Carcinoma Associated With CDC73 Mutation: A Rare Case.

Cureus
2025

MicroRNA-874-3p is a Potential Contributor to Primary Hyperparathyroidism-Induced Osteoporosis.

Clinical interventions in aging
2025

[The single centre experience - from Recklinghausen to the present].

Terapevticheskii arkhiv
2025

The clinical challenge of MEN1 phenocopies: insights from a multicentric national retrospective study.

Journal of endocrinological investigation
2026

Role of MEN1 mutations on postoperative outcomes of patients with multiple endocrine neoplasia type 1-related primary hyperparathyroidism: a single center experience.

Journal of endocrinological investigation
2025

Precision stratified treatment of primary hyperparathyroidism based on multilevel emerging biomarkers.

Frontiers in endocrinology
2025

Novel Variants and Clinical Heterogeneity in Pediatric Calcium Metabolism Disorders Identified Through High-Yield Tiered Genetic Testing in a Taiwanese Cohort.

Medicina (Kaunas, Lithuania)
2025

Autosomal dominant primary hyperparathyroidism in the Keeshond dog breed is strongly associated with a missense variant in sirtuin-6.

Animal genetics
2025

Vitamin D Deficiency as a Debatable Modulator of Outcomes in Transfusion-Dependent Thalassemia; An Overview of the Latest Findings: A Narrative Review.

Health science reports
2025

Atypical Parathyroid Tumor and Hyperparathyroidism, and Their Association With the CDC73 Mutation in a Pediatric Patient.

Cureus
2025

Untying the Next Genetic Thread in a Family With MEN2A Syndrome: A Case Report.

Clinical case reports
2025

Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.

European journal of medical genetics
2026

De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.

American journal of medical genetics. Part A
2025

Familial Aggregation of Primary Hyperparathyroidism and Malignancy-Nationwide Case-Control and Cohort Study.

Journal of the Endocrine Society
2026

Integrated proteomics and bioinformatics reveal the pharmacological mechanism of Shenqi Yanshen granule in chronic kidney disease-mineral and bone disorder (CKD-MBD).

Journal of ethnopharmacology
2025

Bone marrow adipose tissue expansion and bone loss in experimental chronic kidney disease is independent of altered bone marrow stromal cell lineage determination.

Frontiers in endocrinology
2025

Incidental Finding of Combined Factor V and VIII Deficiency in the Setting of a Preoperative Evaluation: A Case Report.

Cureus
2025

Advances in the clinical management of parathyroid disorders: report from the 2024 workshop by the ESE educational program on parathyroid disorders.

European journal of endocrinology
2025

Spatial transcriptomic analysis of mouse parathyroid gland cells expressing an activating variant of Gcm2.

JBMR plus
2025

Persistent Hypercalcemia Despite Parathyroidectomy for Primary Hyperparathyroidism in an Adult with Nephrocalcinosis and Nephrolithiasis Caused by a Novel Combination of Two Pathogenic CYP24A1 Mutations.

International journal of molecular sciences
2025

A novel missense variant of the calcium-sensing receptor gene associated with familial hypocalciuric hypercalcemia.

JBMR plus
2025

Dysregulation of bone and myocardial inorganic phosphate transporters and downstream cell signals in early-stage mild chronic kidney disease-mineral and bone disorder: An experimental study.

Bone
2025

Concurrent Hyperparathyroidism and Wilson's Disease in a Patient With Methanol Toxicity: A Rare Case Report.

Clinical medicine insights. Endocrinology and diabetes
2025

Chronic kidney disease- mineral and bone disorder in autosomal dominant policystic kidney disease.

Bone
2025

Periodontal Manifestations of Systemic Diseases.

Journal of periodontal research
2025

Predictors of MRI-estimated brain iron deposition in dementia and Parkinson's disease-associated subcortical regions: Genetic and observational analysis in UK Biobank.

Journal of Alzheimer's disease : JAD
2025

Genotype-phenotype correlations of germline mutations in exon 10 of the RET proto-oncogene from 14 MEN2A families of Ethnic Han Chinese.

PloS one
2025

Familial hypocalciuric hypercalcaemia type 1 due to a rare CASR missense mutation: a delayed diagnosis in a man with chronic hypercalcaemia.

BMJ case reports
2026

Risk Factors for Pituitary Adenoma Development in Multiple Endocrine Neoplasia Type 1: A Nationwide Study of 240 Cases.

The Journal of clinical endocrinology and metabolism
2025

Clinical Characteristics and Management of Rare Metabolic Bone Diseases: An Audit of the Rare Metabolic Bone Disease Registry of India.

Calcified tissue international
2025

Challenges in the management of jaw tumor syndrome: a case report of pregnancy complicating treatment decision making.

Endocrinology, diabetes &amp; metabolism case reports
2025

Genetic or familiar forms of primary hyperparathyroidism: description of a case series with familial isolated hyperparathyroidism and review of the literature.

Archives of endocrinology and metabolism
2025

French expert consensus statement on diagnosis and management of primary hyperparathyroidism.

Annales d'endocrinologie
2025

CaSR Gene Polymorphisms and PHPT Phenotypes: What Else Can We Learn? A Single-Center Experience on a Cohort of Italian Patients.

Genes
2025

Pseudohypoparathyroidism with normocalcemia: a rare case report from Nepal.

Annals of medicine and surgery (2012)
2025

Atypical pediatric presentation of hyperparathyroidism: CDC73 gene mutation and parathyroid carcinoma.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Long-term epidemiological insights into rickets: a nationwide population-based retrospective study.

Clinical and experimental pediatrics
2025

Familial MEN1 Syndrome with Atypical Renal Features and a Coexisting CLDN16 Variant: A Case Series.

Journal of clinical medicine
2025

A case report of X-linked hypophosphatemia combined with primary hyperparathyroidism.

Frontiers in endocrinology
2025

Recurrent pathological fractures in chronic kidney disease revealing overlapping neglected primary hyperparathyroidism and GDF5-associated skeletal dysplasia.

Archives of osteoporosis
2025

Association of germline variants in the ZFX gene with primary hyperparathyroidism.

PloS one
2025

Diagnosing the silent: the molecular landscape of non-functional parathyroid carcinoma.

Virchows Archiv : an international journal of pathology
2025

A Rare Case of Familial Hypocalciuric Hypercalcemia in Patient With Pancreatitis.

Journal of community hospital internal medicine perspectives
2025

Primary hyperparathyroidism in children: Insights from a single-center cohort.

Pediatric endocrinology, diabetes, and metabolism
2025

Clinical insight into hypercalcemia in children.

Endokrynologia Polska
2025

Familial Thyroid Cancers Syndromes.

Endocrinology and metabolism clinics of North America
2025

Multiple endocrine neoplasia type 1 with neuroglycopenic symptoms with a novel heterozygous MEN1 gene mutation.

World journal of surgical oncology
2025

Management of Primary Hyperparathyroidism: Historical and Contemporary Perspectives.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Novel germline likely pathogenic frameshift variant of the MEN1 gene contributes to multiple endocrine neoplasia type 1: a case report with review of literature.

Endocrine journal
2025

Long-Term Consequences of Misdiagnosis of Parathyroid Adenomas in Pediatric Patients.

Case reports in pediatrics
2025

The role of thymectomy during parathyroidectomy in multiple endocrine neoplasia type 1-associated hyperparathyroidism: a systematic review and meta-analysis.

World journal of surgical oncology
2025

Epidemiology and clinical outcomes of clinically suspected multiple endocrine neoplasia type 1 in South Korea: a nationwide cohort study.

Frontiers in endocrinology
2025

Differential diagnosis of heritable and acquired osteomalacia in children: biochemical and biomaterial signatures.

Calcified tissue international
2025

Hyperparathyroidism-Jaw Tumor Syndrome Associated to a CDC73 Gene Pathogenic VARIANT and a Nonossifying Desmoplastic Fibroma of the Mandible.

Case reports in endocrinology
2025

Updated Recommendations for Pediatric Surveillance in Hereditary Endocrine Neoplasia Syndromes: Multiple Endocrine Neoplasias, Hyperparathyroidism-Jaw Tumor Syndrome, and Carney Complex.

Clinical cancer research : an official journal of the American Association for Cancer Research
2025

Endocrinopathies associated with pediatric common variable immunodeficiency.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Sporadic Coexistence of Parathyroid Adenoma, Papillary Thyroid Carcinoma, Pheochromocytoma, and Cardiac Myxoma: A Multidisciplinary Approach to an Extremely Rare Tumor Constellation.

Cureus
2025

Recurrent acute pancreatitis as an initial presentation of primary hyperparathyroidism in juvenile patient.

World journal of clinical cases
2025

Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis.

The lancet. Diabetes &amp; endocrinology
2025

PHEX Protein in the Parathyroid Gland Contributes to Phosphate Sensing.

The Journal of clinical endocrinology and metabolism
2025

Single cell sequencing revealed parathyroid oxyphil cells are involved in osteoporosis under primary hyperparathyroidism.

Frontiers in endocrinology
2025

Causal validation between 179 lipids and hyperparathyroidism: A bidirectional Mendelian randomization combined meta-analysis with mediation factors.

Medicine
2025

Multiple endocrine neoplasia type 2A: a diagnostic challenge case report.

Annals of medicine and surgery (2012)
2025

Double mutation for multiple endocrine neoplasia associated with congenital adrenal hyperplasia.

Endocrinology, diabetes &amp; metabolism case reports
2025

Rapid development of diffuse hepatic calcification in a patient with congenital hepatic fibrosis and secondary hyperparathyroidism.

Clinical journal of gastroenterology
2025

A Pituitary Macroadenoma Cosecreting Prolactin and Growth Hormone in a Patient With Multiple Endocrine Neoplasia Type 4.

JCEM case reports
2025

Case report: Clinical and genetic characteristics of heterozygous CaSR variants in three Chinese females with familial hypocalciuric hypercalcemia type 1: a report of three cases.

Frontiers in genetics
2025

[Genetic profiling of parathyroid tumours: lifting the veil of mystery].

Problemy endokrinologii
2025

Identifying Kidney Stone Risk Factors Through Patient Experiences With a Large Language Model: Text Analysis and Empirical Study.

Journal of medical Internet research
2025

miRNAs in secondary hyperparathyroidism: literature review.

BMC nephrology
2025

Clinical phenotypes and genetic screening in hereditary primary hyperparathyroidism: A single-center case series.

Annales d'endocrinologie
2025

Persistent Hyperparathyroidism in Vitamin D-Dependent Rickets Type 2A Does Not Prevent Normalization of Hypophosphatemia or Healing of the Rickets.

Hormone research in paediatrics
2025

Renal insufficiency caused by TMEM216 gene mutation: Case Report.

Frontiers in medicine
2025

An Updated Perspective of the Clinical Features and Parathyroidectomy Impact in Primary Hyperparathyroidism Amid Multiple Endocrine Neoplasia Type 1 (MEN1): Focus on Bone Health.

Journal of clinical medicine
2025

Radiation-Induced Synchronous Parathyroid Carcinoma and Papillary Thyroid Carcinoma: Clinical, Morphological, and Genetic Insights.

International journal of molecular sciences
2025

Case Report: Late diagnosis of McCune-Albright with severe kyphoscoliosis, acromegaly and tertiary hyperparathyroidism.

Frontiers in endocrinology
2025

A Rare Case of a Giant Parathyroid Adenoma in a Young Male Patient.

Cureus
2025

MEN2: surgical precision in the era of precision medicine.

Endocrine-related cancer
2025

Biased antibodies and beyond: a new era in the diagnosis of PTH-dependent hypercalcemia.

Endocrine journal
2025

Endocrine and Neuroendocrine Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book".

Archives of pathology &amp; laboratory medicine
2025

Idiopathic Hypercalciuria: A Comprehensive Review of Clinical Insights and Management Strategies.

Cureus
2025

Germline mutations of GCM2 cause a novel variant of hereditary primary hyperparathyroidism.

Updates in surgery
2025

Diabetic Ketoacidosis With Schmidt Syndrome: An Autoimmune Polyendocrine Syndrome Type 2.

Cureus
2025

Predictors of Mortality in Patients With Multiple Endocrine Neoplasia Type 1.

Clinical endocrinology
2025

Primary renal tubular acidosis during pregnancy, what about the perinatal prognosis? A case report and literature review.

Nefrologia
2025

An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.

Diseases (Basel, Switzerland)
2025

A literature review of the healthcare resource use and productivity burden of X-linked hypophosphataemia.

Frontiers in health services
2025

Leptin regulates parathyroid hormone secretion through CaSR-ERK1/2 signaling.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2025

Advancing patient evidence in XLH (APEX): rationale and design of a real-world XLH global data unification program.

Frontiers in endocrinology
2025

Dendrimer nanocarriers for targeted co-delivery of MiR-146b-3p and 5-ALA to synergistic photodynamic therapy in secondary hyperparathyroidism.

International journal of biological macromolecules
2025

Importance of early detection in multiple endocrine neoplasia type 1: Clinical insights and future directions.

World journal of gastrointestinal oncology
2025

Vitamin D dependent rickets type 2A: a case series of two siblings with novel mutation in vitamin D receptor gene responded to high dose oral calcium and calcitriol.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Insulinoma: A Novel Presentation of Multiple Endocrine Neoplasia 4.

AACE clinical case reports
2025

A Novel Mutation in a Family With Multiple Endocrine Neoplasia Type 1 and Aggressive Pancreatic Neuroendocrine Tumors.

AACE clinical case reports
2025

[Novel mutations in the calcium-sensing receptor encoding genes as a cause of familial hypocalciuric hypercalcemia].

Medicina
2025

Vitamin D receptor: a possible biomarker for sporadic parathyroid adenoma?

Updates in surgery
2025

Oncocytic Tumors in the Familial and Syndromic Contexts: A Tri-Focal Review - Integrated Cytopathological, Pathological, and Molecular Perspectives.

Acta cytologica
2025

Hyperparathyroidism-Jaw Tumor Syndrome: A Rare Case Report and Literature Review.

Clinical case reports
2025

Microbial Influences on Calcium-Phosphorus Homeostasis and Metabolic Bone Diseases: A Bidirectional Mendelian Randomisation Study on the Gut-Bone Axis.

Journal of cellular and molecular medicine
2025

Molecular mechanism for transcriptional regulation of the parathyroid hormone gene by Epiprofin.

The FEBS journal
2025

Management and Long-Term Monitoring of a Young Patient with Pheochromocytoma and RET Mutation: A Case Report.

International medical case reports journal
2025

Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome Clinical Presentation and the Role of Newer Functional Imaging in the Diagnosis and Management: A Case Report.

Cureus
2025

Multiple endocrine neoplasia type 1 in childhood and description of a novel variant.

Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo
2025

Hyperparathyroidism-Jaw Tumor Syndrome: A Case Diagnosed After the Removal of Multiple Ossifying Fibromas of the Jaws.

JCEM case reports
2025

A Novel Multiple Endocrine Neoplasia Type 1 Gene Variant Found in Scalp Pulmonary Neuroendocrine Tumor Metastasis.

JCEM case reports
2025

Post-surgical natural history of MEN2A with RET C634R mutation and bilateral cervical node metastasis: a case report.

Annals of medicine and surgery (2012)
2025

Primary Hyperparathyroidism in MEN2 Syndromes.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Serendipitous Discovery and Characterization of Two Different Pathologies on 68 Ga-DOTATATE and 68 Ga-Exendin PET/CT in a Patient With Hyperinsulinemic Hypoglycemia Leading to Diagnosis of MEN-1.

Clinical nuclear medicine
2024

A Pilot Study of ANXA2, MED12, CALM1 and MAPK1 Gene Variants in Primary Hyperparathyroidism.

Balkan journal of medical genetics : BJMG
2025

Heritable hyperparathyroidism: Genetic insights and clinical implications.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2025

Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2025

Management of primary hyperparathyroidism in MEN1: From initial subtotal surgery to complex treatment of the remaining gland.

Annales d'endocrinologie
2025

Fgf23 expression increases atherosclerotic plaque burden in male ApoE deficient mice.

Atherosclerosis
2025

Use of Olaparib in the Management of Metastatic Parathyroid Carcinoma With BRCA1 Mutation.

JCEM case reports
2025

Multiple endocrine neoplasia type 1: Early diagnosis is very important.

World journal of gastroenterology
2025

Congenital primary hyperparathyroidism.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2025

Multiple Endocrine Neoplasia Type 1 With Adrenal Cortical Adrenocortical Carcinoma: A 25-Year Follow-Up and Family Report.

JCEM case reports
2025

Phosphate metabolism in primary hyperparathyroidism: a real-life long-term study.

Endocrine
2025

Exploring the causal relationship between GLP-1R agonists and diseases related to the thyroid and parathyroid: a mendelian randomization study.

Journal of diabetes and metabolic disorders
2025

Mitochondrial dysfunction and mitophagy blockade contribute to renal osteodystrophy in chronic kidney disease-mineral bone disorder.

Kidney international
2025

Changing trends in clinical presentation of primary hyperparathyroidism across countries over time.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2025

Association of primary hyperparathyroidism with pituitary adenoma and management issues.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2025

Renal Neoplasia: Rare Subtypes and Uncommon Clinical Presentations.

Surgical pathology clinics
2024

Case report: Relapse of intrathyroidal parathyroid carcinoma in a patient with novel variants in MET and CDKN1C genes.

Frontiers in oncology
2025

Aerobic exercise prevents renal osteodystrophy via irisin-activated osteoblasts.

JCI insight
2025

A Novel Pathogenic CDC73 Gene Variant in Hyperparathyroidism-jaw Tumor Syndrome.

JCEM case reports
2025

Unusual presentation and management of parathyroid carcinoma with pulmonary metastasis: a case report.

AME case reports
2025

Neonatal severe hyperparathyroidism with inactivating calcium sensing receptor (CaSR) mutation (p.I81K).

Journal of pediatric endocrinology &amp; metabolism : JPEM
2024

Medullary thyroid cancer in MEN2 pediatric/adolescent carriers of RET mutation: genotype/phenotype correlation and outcome in a retrospective series of 23 patients.

Frontiers in oncology
2025

Biting off more than you can chew: a rare case of hyperparathyroidism jaw tumour syndrome.

Oxford medical case reports
2024

Case report: Prolonged and severe hungry bone syndrome after parathyroidectomy in X-linked hypophosphatemia.

Frontiers in endocrinology
2025

PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas.

The Journal of clinical endocrinology and metabolism
2025

Progress report on multiple endocrine neoplasia type 1.

Familial cancer
2025

Adolescent primary hyperparathyroidism.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2025

Chapter 15: Recurrent or persistent primary hyperparathyroidism, parathyromatosis.

Annales d'endocrinologie
2025

Chapter 5: The roles of genetics in primary hyperparathyroidism.

Annales d'endocrinologie
2025

Chapter 8: Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor.

Annales d'endocrinologie
2025

Chapter 6: Syndromic primary hyperparathyroidism.

Annales d'endocrinologie
2025

Chapter 0: Introduction to the consensus on primary hyperparathyroidism from the French Society of Endocrinology, French speaking Association of Endocrine Surgery and French Society of Nuclear Medicine.

Annales d'endocrinologie
2025

Chapter 7: The different forms of primary hyperparathyroidism at different ages of life: Childhood, pregnancy, lactation, old age.

Annales d'endocrinologie
2025

Chapter 4: Differential diagnosis of primary hyperparathyroidism.

Annales d'endocrinologie
2025

Chapter 1: Epidemiology of primary hyperparathyroidism.

Annales d'endocrinologie
2024

Retrospectively diagnosed familial hypocalciuric hypercalcaemia following total parathyroidectomy in an asymptomatic patient.

EJIFCC
2025

Differences in association between hypoalbuminaemia and mortality among younger versus older patients on haemodialysis.

Clinical kidney journal
2025

[Clinical and genetic characteristics analysis of two children with comorbidity of two rare genetic diseases].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

Bone Health ECHO Case Report: High Bone Mass in a Patient with Chronic Kidney Disease.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
2025

Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.

The Journal of clinical endocrinology and metabolism
2025

The Delicate Balancing of Pros and Cons in the Surgical Management of Hyperparathyroidism in a Young Female with Germline Variant in the CDC73 Gene.

Calcified tissue international
2025

Tatton-Brown-Rahman syndrome: A new multiple endocrine neoplasia syndrome with intellectual disability?

Annales d'endocrinologie
2024

Genotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.

Frontiers in endocrinology
2024

Atypical Presentation of Primary Hyperparathyroidism.

Cureus
2024

Demineralization of Osseous Structures as Presentation of a Rare Genetic Disorder That Is Associated With a High Rate of Mortality.

Case reports in endocrinology
2025

Characteristics of lipid metabolism and fat distribution in patients with primary hyperparathyroidism and their Mendelian randomization study.

Endocrine
2025

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study.

Blood
2024

Primary hyperparathyroidism due to a giant parathyroid adenoma presenting with pathological fractures and multiple brown tumors.

Endocrinology, diabetes &amp; metabolism case reports
2024

Reviewing the Possible Rare Reasons for Normal Parathyroid Hormone, Vitamin D and Serum Calcium Levels in a Patient With Severe Osteoporosis and Radiologic Parathyroid Adenoma: A Case Report.

Cureus
2024

Intestinal Cyp24a1 regulates vitamin D locally independent of systemic regulation by renal Cyp24a1 in mice.

The Journal of clinical investigation
2025

CDC73 c.1155-3A>G is a pathogenic variant that causes aberrant splicing, disrupted parafibromin expression, and hyperparathyroidism-jaw tumor syndrome.

JBMR plus
2024

Prevalence of the major thyroid cancer-associated syndromes in the United States.

medRxiv : the preprint server for health sciences
2025

Singular case report of familial hypocalciuric hypercalcemia: a rare diagnosis of hypercalcemia in the older people.

The aging male : the official journal of the International Society for the Study of the Aging Male

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Hiperparatireoidismo genético.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Hiperparatireoidismo genético

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Treating microsatellite unstable metastatic parathyroid carcinoma with anti-PD1 therapy.
    JCEM case reports· 2026· PMID 41878704mais citado
  2. How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.
    Annales d'endocrinologie· 2026· PMID 41866073mais citado
  3. A novel homozygous inactivating mutation of the calcium-sensing receptor causing familial hypocalciuric hypercalcemia complicated with primary hyperparathyroidism due to parathyroid adenoma: A case report.
    The Journal of international medical research· 2026· PMID 41852233mais citado
  4. [Multiple endocrine neoplasia syndrome type&#xa0;1: analysis of data from 102&#xa0;patients from 43 families in the population of the Russian Federation].
    Problemy endokrinologii· 2026· PMID 41834593mais citado
  5. Hyperparathyroidism drives periodontitis progression via parathyroid hormone-induced endoplasmic reticulum stress.
    Biochemical and biophysical research communications· 2026· PMID 41771208mais citado
  6. Vision screening of Greenlandic children evaluating efficacy, coverage and future directions.
    Acta Ophthalmol· 2026· PMID 41994901recente
  7. A zero-inflated hierarchical generalized transformation model to address non-normality in spatially-informed cell-type deconvolution.
    Biometrics· 2026· PMID 41994891recente
  8. Setmelanotide in Bardet-Biedl Syndrome: A Case Report.
    Pediatr Dermatol· 2026· PMID 41994885recente
  9. From shelter to stroke: A mediation-proxy analysis of homelessness-associated stroke risk in dialysis patients.
    Clin Nephrol· 2026· PMID 41994878recente
  10. Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHD.
    Nucleic Acids Res· 2026· PMID 41994867recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:208596(Orphanet)
  2. MONDO:0016166(MONDO)
  3. GARD:20408(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55785987(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Hiperparatireoidismo genético
Compêndio · Raras BR

Hiperparatireoidismo genético

ORPHA:208596 · MONDO:0016166
MedGen
UMLS
C5680826
Repurposing
6 candidatos
calcifediolvitamin D receptor agonist
cinacalcetcalcium channel activator
clodronic-acidbone resorption inhibitor
+3 outros
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades